Takeda Oncology

Oncology

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...

Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.

News

Takeda builds in cancer with monster $11.4bn Innovent deal

Takeda has partnered with China's Innovent for a pair of late-stage cancer therapies, in a deal that includes an upfront payment of $1.2bn.

Oncology

Jonah Comstock and Thanos Zomas at ASCO 2024

ASCO 2024 – Thanos Zomas

Great advances in cancer care have led to a new phase of research in certain cancers – in areas where a high rate of cure has been established, the focus is shifting to quality of life, sid

Views & Analysis

Cutting the combination therapy access issue down to size

While the access to combination treatments problem is nothing new, its sheer magnitude means it has, to date, gone unsolved.

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...

Takeda builds in cancer with monster $11.4bn Innovent deal

ASCO 2024 – Thanos Zomas

Cutting the combination therapy access issue down to size

EMA advisors say CSL's Tavneos should be pulled from sale

Discover a new era of healthcare panel engagement: Grounded ...

Takeda Oncology

Editor's Picks